Shares of Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) were up 6.5% during trading on Wednesday . The company traded as high as $0.65 and last traded at $0.65. Approximately 2,103 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 16,610 shares. The stock had previously closed at $0.61.
Humacyte Stock Performance
The company has a 50 day simple moving average of $0.69 and a 200 day simple moving average of $0.56.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Further Reading
- Five stocks we like better than Humacyte
- Stock Average Calculator
- High-Yield Texas Instruments Could Hit New Highs Soon
- How to Read Stock Charts for Beginners
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
